Modra Pharmaceuticals
Jan Schellens is a highly experienced individual in the field of medical oncology and clinical pharmacology. With an extensive background in translational research and early clinical development, Jan has held various leadership positions in prestigious organizations such as Modra Pharmaceuticals, Byondis, and Debiopharm. Throughout their career, Jan has also made significant contributions in academic settings, serving as a professor at Utrecht University and holding positions at The Netherlands Cancer Institute and Dr Daniel den Hoed Kliniek-ErasmusMC. Jan holds multiple degrees in medicine, pharmacology, and pharmaceutical sciences, and continues to further their education through the European Certified Pharmacologists Programme.
This person is not in the org chart
This person is not in any teams
Modra Pharmaceuticals
Modra (Modulated Oral Drug Absorption) Pharmaceuticals B.V. is a spin-out from two internationally acclaimed centers of excellence in oncology, the ‘Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)’ and the MC Slotervaart (Slotervaart) in Amsterdam. Modra Pharmaceuticals is a clinical stage company that develops new treatment paradigms by enabling oral bioavailability of existing anticancer drugs, “the iv to oral switch”, to improve cancer therapy and supportive care. Modra Pharmaceuticals has several products in preclinical and clinical development including oral formulations of docetaxel and paclitaxel.